An arcane cardiomyopathy by J. R. T. C. Roelandt
SHORT COMMUNICATION
An arcane cardiomyopathy
J. R. T. C. Roelandt
Published online: 26 September 2014
# The Author(s) 2014. This article is published with open access at Springerlink.com
Last February, the Lancet and the New England Journal of
Medicine almost simultaneously published two interesting
case reports on an arcane cardiomyopathy [1, 2]. The New
York Times drew attention to these papers in their Health
Section as ‘A Medical Mystery Solved’.
A 55-year-old man is described. He was hospitalised for
severe heart failure after he had gone from doctor to doctor
seeking a diagnosis for his many puzzling ailments. His left
ventricular ejection fraction was 25 % and his coronary arte-
riogram normal. In 2010 his ceramic artificial hip was re-
placed by a metal-on-metal type, which to the doctors had
seemed unrelated to his many symptoms (heart failure, deaf-
ness, almost blind, hypothyroidism, and fever). However, a
doctor of the team in Marburg (Germany) remembered an
episode of Dr. House that he watched on the Fox TV show
(also broadcast in Germany and in the Netherlands), on a
mysterious illness caused bymetal poisoning from an artificial
metal hip. When they measured the patient’s blood serum
cobalt level it was 1000 times higher than normal. Radiogra-
phy showed metal debris near his metal hip. After chelation
therapy and replacement of his metal hip with a ceramic type,
his condition improved and his ejection fraction rose from 25
to 40 %. Cobalt intoxication was the most likely cause of the
heart failure and the many other ailments of this patient [1].
The other report describes a 59-year-old woman who
underwent heart transplantation for severe heart failure, also
after a few years of puzzling complaints and symptoms. In her
work-up all rare causes of her medical history were considered
but none showed up. She had undergone right total hip re-
placement 4 years previously and left total hip replacement
3 years previously, both with a metal prosthesis. Sometime
after her heart transplantation her orthopaedist unexpectedly
found her blood serum cobalt level to be 300 times higher than
normal on a routine check-up. A year later both artificial hips
were replaced with prostheses with a polyethylene liner. Her
cobalt levels decreased and her condition improved. The most
likely cause of her symptoms and unexplained heart failure
was cobalt intoxication [2].
Since 2006, there is an increasing number of publi-
cations on patients with problems after a metal-on-metal
hip arthroplasty. As a result of the wear over time at the
bearing surfaces, chromium and cobalt are commonly
found in the blood and urine of these patients. In the
vicinity of the prosthesis, the metal ions can cause
metallosis resulting in giant cell infiltration, fibrosis
and solid pseudotumours [3–6]
In 2010, Tower was the first to draw attention to the
neurological and cardiac adverse effects of chronic systemic
cobaltism [7]. Subsequently, a few case reports have been
published on cobalt cardiomyopathy, one with fatal outcome
[1, 2, 8–10].
When I was starting my fellowship in cardiology at the
University of Leuven (B) in 1966, my mentor, Professor H.
Kesteloot published a series of patients with severe heart
failure. All were heavy beer drinkers. Strangely enough, these
patients had a large pericardial effusion and polycythaemia,
two findings which had not been reported before in alcoholic
cardiomyopathy. Also, after tapping the fluid, their heart size
was not significantly enlarged. The syndrome was presented
as a new form of cardiomyopathy in chronic beer drinkers
[11].
Early in 1967, there was a request from the FDA as to
whether they could come to Leuven to examine the files of
these patients. After studying the data, they told us the story of
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the Quebec beer drinkers, about the similarities between the
two groups and that cobalt intoxication was the most likely
cause [12, 13].
Between August 1965 and April 1966, 48 patients, all
heavy drinkers, were admitted to the Department of Cardiol-
ogy of the Laval University of Quebec (Canada) and 20 of
them had died. All patients were drinking beer of the Dow
Brewery. This brewery had been adding cobaltous sulphate to
their beer since July 1965 to stabilise the foam layer. Analysis
showed that that brand of beer contained 10 times more of the
chemical than other beers. The rapid decrease of the foam
layer was an increasing problem due to the washing of the
glasses with detergents (women increasingly frequented bars
in the 1960s and lipstick could not be removed from the
glasses by just rinsing in plain water). In the same period,
the chemical had also been added to the beer in breweries in
Omaha (Nebraska, US). In three hospitals, 64 patients were
admitted of whom 40 died [14].
Together with my co-fellow J. Willems we traced the
‘Leuven’ patients, convinced them to come to the clinic for
clinical re-examination and blood analysis, ECG and asked
them the brands of beer they were drinking to test for their
cobalt content. All patients drank beer containing cobalt [15].
The similarities of the medical history of the patients in
Quebec, Omaha and Leuven led to the conclusion that the
aetiological role of cobalt could be accepted as proven. The
synergistic toxic effect of alcohol and cobaltaemia was later
confirmed in experimental studies [13, 16].
The addition of cobaltous sulphate (or cobaltous chloride)
to beer to stabilise the foam layer was patented and distributed
by A. Jorgenson Laboratories in Copenhagen. It was removed
from the market in 1967.
In the recent edition of his textbook Heart Disease,
Braunwald mentions that no single case of the acute and
severe form of cobalt cardiomyopathy has been reported since
[17].
Some questions remain. Why did none of our patients
die and why did only a small fraction of the population
drinking cobalt containing beer develop heart disease? This
could be due to an abnormal sensitivity and/or to a synergic
action of different factors in certain individuals. Nutritional
deficiencies definitely played a crucial role. All patients
were anorexic, had a lower economic status and had an
inadequate protein intake. However, our patients regularly
consumed hard boiled eggs (barkeepers in Belgium often
offered boiled eggs to their loyal customers) containing a
lot of sulfhydryl amino acids (cysteine, methionine), which
form an irreversible chelate with cobalt and effectively
eliminates cobalt.
The serum blood levels of cobalt in arthroplasty patients
and in cases of industrial exposure to cobalt are much higher
than they were in the beer drinkers.Why, then, is the incidence
of a toxic cardiomyopathy so low? In general, the nutritional
status of these patients is good and the alcohol intake in the
large majority limited. Cobalt blocks the oxidative metabo-
lism at the mitochondrial level resulting in cellular dysfunc-
tion or death, but the factors which determine cardiac toxicity
in chronic cobaltaemia are certainly multifactorial and largely
unknown.
Many patients with a metal hip prosthesis are in the older
age group in which heart disease is more prevalent. Cardiol-
ogists should be aware of the potential toxic and systemic
adverse effects of cobalt (tinnitus, vertigo, deafness, visual
changes, hypothyroidism, neuropathy and heart failure) as
chronic elevated cobaltaemia may have an additional effect
on a co-existing myopathy.
Over 10,000 patients have received a metal-on-metal hip
prosthesis in the Netherlands since 1999 and about 10–15 %
have been replaced (Bom LPA. Personal communication
2014). In April 2010, the UK Medical Products and
Healthcare Devices Regulatory Agency published the first
medical device alert (and an update in 2012) and recommend-
ed to monitor all patients with a metal-on-metal hip
arthroplasty for cobalt toxicity symptoms [18]. In 2008 the
Dutch Orthopaedic Association started a national registry of
all hip implants, the LROI (Landelijke Registratie
Orthopedische Implantaten). Because of the apparent side
effects, the Dutch Orthopaedic Association strongly advised
their members against the use of metal-on-metal hip prosthe-
ses and advised yearly follow-up of all patients with such a
prosthesis. Patients with a serum blood cobalt level>40 nmol/
L require close surveillance for signs and symptoms of cobalt
toxicity [19].
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In memoriam Prof. dr. Jos R.T.C. Roelandt
Sunday, August 31th, 2014, prof. dr. Jos R.T.C. Roelandt suddenly passed away. The above-published article on cobalt intoxication
in the Netherlands Heart Journal is therefore (presumably) his last publication. Prof. Roelandt published well over 600 international
articles, the majority addressing a variety of echocardiographic topics. Jos Roelandt can be considered as a world-wide known
pioneer in the field of echocardiography introducing this ‘new’ noninvasive imaging technique in the 19-seventies at the Thorax
Centre in Rotterdam. In the late 19-seventies, Roelandt started to organize courses in echocardiography. I myself followed his very
first course whereby Roelandt at that time already proclaimed that echocardiography was one of the greatest discoveries in
cardiology and would never be displaced by any other technique. He forecasted the future right; despite major evolutions in
cardiovascular imaging such as nuclear cardiology, magnetic resonance imaging, and computed tomography, echocardiography has
withstood modern approaches and has even expanded its spectrum to intravascular ultrasound, 3D-echocardiography, contrast
echocardiography, tissue Doppler imaging, speckle tracking etc.
With the untimely death of Jos Roelandt we lose one of the primary voices of echocardiography, blazing the trail for many
clinicians and scientists. Ironically, not only his last publication dealt with cobalt intoxication but also his very first paper in
1966. Publication-wise, the circle of life seems round. I wish his family much strength in the time to come.
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Editor-in-Chief Netherlands Heart Journal
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